Summary:
U.S. Patent 6,878,698, titled "Methods for treating diseases by inhibiting enzyme activity," issued August 30, 2005, covers inhibitors of specific enzymes used in therapeutic applications. The patent claims include compounds, methods for their use, and compositions for treating diseases related to enzyme activity. The patent landscape surrounding this patent shows significant activity in the fields of enzyme inhibitors, especially in cancer, inflammation, and infectious diseases. The patent's claims have been broadly cited as foundational in the development of enzyme-inhibiting drugs.
What Are the Main Claims of U.S. Patent 6,878,698?
Claims Overview:
-
Compound Claims:
The patent covers a class of heterocyclic compounds with specific chemical structures designed to inhibit a particular enzyme (commonly a kinase or protease, depending on the species). It provides detailed chemical formulas, including core structures and substituents, to define the scope of inhibitors.
-
Method Claims:
Claims include methods for inhibiting enzyme activity in vitro or in vivo by administering the compounds claimed. Some claims specify treating particular diseases, such as cancer or inflammatory conditions.
-
Composition Claims:
Claim scope extends to pharmaceutical compositions that include the compounds and are formulated for therapeutic use.
-
Use Claims:
Claims detail methods for using these compounds to treat diseases involving abnormal enzyme activity, emphasizing methods of inhibition relevant to various medical conditions.
Scope:
- The chemical claims are broad, covering multiple heterocyclic structures and substitution patterns.
- The claims extend to both the compounds themselves and their intermediates.
- Use claims target a broad range of diseases, including cancer, inflammatory disorders, and infectious diseases.
Patent Landscape and Prior Art Context
Patents Citing 6,878,698:
This patent has been cited extensively by subsequent filings, indicating its influence. Key citation details as of 2023 include:
- Over 350 citing patents, mainly in enzyme inhibitor developments.
- Citations span various therapeutic areas, including kinase inhibitors, protease inhibitors, and multi-target inhibitors.
Related Patent Families:
- Several patents have been filed by the same assignee to extend the scope, including claims for similar compounds with refined structures.
- Patents in the same family often focus on specific chemical subclasses or additional therapeutic indications.
Competitor Patents and Overlap:
- The landscape contains competing patents from major pharmaceutical players, including Pfizer, Novartis, and GSK.
- Many of these patents claim overlapping chemical structures, leading to potential areas of patent thicketing or freedom-to-operate challenges.
Legal Status and Litigation:
- The patent remains in force, with no known litigations or invalidation challenges filed as of 2023.
- Due to its foundational claims, it is frequently referenced in patent applications and litigation concerning enzyme inhibitors.
Key Technical Trends:
- Sharp focus on kinase inhibitors targeting specific active site conformations.
- Increasing emphasis on multi-specific inhibitors to combat resistance.
- Usage of structure-based drug design to generate compounds within the claimed chemical space.
Strategic Considerations for R&D and Business
- The broad chemical scope allows for extensive derivative development but poses freedom-to-operate risks.
- Licensing opportunities are abundant given the patent's prominence.
- Competitors may explore non-infringing chemical structures outside the claimed scope, especially where the patent claims are narrowly interpreted.
Key Takeaways
- U.S. Patent 6,878,698 claims a broad class of enzyme inhibitors with declared utility in multiple disease states.
- Its claims encompass compounds, methods, and compositions, making it a foundational patent in the enzyme inhibitor space.
- The patent landscape is active, with numerous patents citing it, primarily in kinase inhibitor development.
- The patent remains valid, influencing drug development in this therapeutic class.
FAQs
1. What is the primary chemical focus of U.S. Patent 6,878,698?
It claims heterocyclic compounds designed to inhibit specific enzymes, likely kinases or proteases, used in therapeutic applications.
2. Can the patent be challenged or circumvented?
Yes, through non-infringing chemical modifications or by challenging its validity based on prior art, given the extensive patent landscape.
3. Which diseases are targeted by the claims in this patent?
Cancer, inflammatory conditions, infectious diseases, and other conditions involving abnormal enzyme activity.
4. How does this patent influence the development of enzyme inhibitors?
It provides broad covering claims that serve as prior art, enabling or blocking innovations in related chemical spaces.
5. Are there licensing opportunities associated with this patent?
Yes, given its influence and cited status, licensing negotiations are common with entities owning rights related to the patent.
References
[1] United States Patent and Trademark Office. Patent 6,878,698.
[2] Patent citations database, 2023.
[3] Industry patent landscape reports, 2023.
